Charles River Laboratories Announces Senior Mgt Changes


From DCAT Value Chain Insights (VCI)

By People On The Move posted 03-03-2015 07:45

  

Charles River Laboratories International, Inc., a contract research organization, has announced planned management changes that will be implemented over the course of 2015, which includes a new chief financial officer (CFO).

Thomas F. Ackerman, current corporate executive vice president and CFO, will retire in February 2016. Mr. Ackerman joined Charles River in 1988, with over a decade of combined public accounting and international finance experience. He became vice president and CFO in 1996 and was elevated to his current position in 2005.

David R. Smith, corporate senior vice president, global discovery services, has been named as Mr. Ackerman’s successor. Mr. Smith joined Charles River through the company's acquisition of Argenta and BioFocus from Galapagos NV, where he was serving as chief executive officer of its Galapagos Services division. Mr. Smith spent eight years at PricewaterhouseCoopers prior to joining AstraZeneca in 1997, where he spent the next nine years in various finance and business roles of increasingly greater responsibility. After leaving AstraZeneca, Mr. Smith served as the CFO of Galapagos NV before becoming CFO for Cambridge University Hospitals, where he served in that capacity for six years, from 2007 to 2013.

Once Mr. Smith assumes the corporate executive vice president and CFO role, Dr. Emily Hickey will be promoted to the position of corporate senior vice president, global discovery services. Before joining Charles River, Dr. Hickey was the executive director of in vivo pharmacology at Merck Research Labs, leading the development and implementation of the externalization strategy for in vivo studies. Most recently, Dr. Hickey has served as corporate vice president, In Vivo Discovery, overseeing Charles River's in vivo discovery businesses in the United States and Europe. Dr. Katherine Hilyard, managing director, BioFocus DPI Ltd., will be promoted to the position of corporate vice president, early discovery, and will assume responsibility for the Argenta, BioFocus, and ChanTest businesses, which comprise the company's early discovery business.

Source: Charles River

0 comments
46 views


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription 

Permalink